Editorial
|
|
|
|
|
International nonproprietary names are meaningful; brand names are not
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival
|
|
|
|
|
|
|
|
|
|
|
|
An advance in very rare hereditary bile acid synthesis defects
|
|
|
|
|
|
|
|
|
|
Asthma and COPD: yet another beta-2 agonist and corticosteroid combination
|
|
|
|
|
|
|
|
|
|
COPD: just another beta-2 agonist
|
|
|
|
Adverse Effects
|
|
|
|
|
Harms have been expected and are confirmed
|
|
|
|
|
|
|
|
|
|
|
|
A growing list of adverse effects
|
|
|
|
|
|
|
|
|
|
Following drug introduction or dose increase
|
|
|
|
|
|
|
|
|
|
A poor option in urinary incontinence
|
|
|
|
|
|
|
|
|
|
Poor harm-benefit balance
|
|
|
|
Reviews
|
|
|
|
|
Oral non-sedating antihistamines without antimuscarinic effects
|
|
|
|
|
|
Outlook
|
|
|
|
|
Notable changes in the 2016 update: citalopram, escitalopram, diclofenac added to the list of drugs to avoid
|
|
|
|
|
|
|
|